NASDAQ · Financial Statements

Ultragenyx Pharmaceutical Inc. (RARE) Revenue, Earnings & Financial Statements

$16.70 NASDAQ: RARE Market Cap $1.70B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Ultragenyx Pharmaceutical Inc. most recently reported annual revenue of $673.0M, a net loss of $575.0M. Revenue grew at an average annual rate of 20.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Ultragenyx Pharmaceutical Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -186471.4% to -79.5%, a shift of +186391.9 percentage points; the most recent year shows a net loss of $575.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$3.0M$51.0M$104.0M$271.0M$351.0M$363.0M$434.0M$560.0M$673.0M
Operating Expenses$248.0M$332.0M$423.0M$528.0M$601.0M$733.0M$1.0B$1.0B$1.1B$1.2B
Operating Profit−$248.0M−$329.0M−$371.0M−$424.0M−$330.0M−$382.0M−$649.0M−$569.0M−$536.0M−$535.0M
Operating Margin-186471.4%-12593.5%-721.2%-409.0%-121.8%-108.6%-178.6%-131.1%-95.7%-79.5%
Other Income$2.0M$11.0M$174.0M$25.0M$145.0M−$71.0M−$53.0M−$39.0M−$32.0M−$36.0M
Interest$0$0$0$1.0M$33.0M$29.0M$43.0M$66.0M$63.0M$62.0M
Depreciation$3.0M$6.0M$20.0M$9.0M$12.0M$13.0M$18.0M$26.0M$36.0M$35.0M
Profit Before Tax−$246.0M−$318.0M−$197.0M−$399.0M−$185.0M−$453.0M−$702.0M−$608.0M−$568.0M−$571.0M
Tax rate (%)-0.0%5.1%-0.3%-0.8%-0.7%-0.2%-0.8%0.3%-0.3%-0.7%
Net Profit−$246.0M−$302.0M−$198.0M−$403.0M−$187.0M−$454.0M−$707.0M−$607.0M−$569.0M−$575.0M
EPS−$6.21−$7.12−$3.97−$7.12−$3.07−$6.70−$10.12−$8.25−$6.29−$5.83

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$127.0M$109.0M$147.0M$139.0M$165.0M$139.0M$166.0M$160.0M$207.0M$136.0M$214.0M$173.0M
Operating Expenses$249.0M$274.0M$263.0M$271.0M$287.0M$282.0M$274.0M$331.0M$321.0M$305.0M$289.0M$283.0M
Operating Profit−$122.0M−$165.0M−$116.0M−$132.0M−$122.0M−$143.0M−$108.0M−$171.0M−$114.0M−$169.0M−$75.0M−$110.0M
Operating Margin-95.8%-151.9%-79.1%-94.6%-74.2%-102.6%-64.8%-106.8%-55.1%-124.3%-35.0%-63.6%
Interest$17.0M$16.0M$16.0M$16.0M$16.0M$14.0M$14.0M$14.0M$19.0M$21.0M$22.0M$20.0M
Profit Before Tax−$127.0M−$170.0M−$131.0M−$133.0M−$133.0M−$150.0M−$114.0M−$180.0M−$128.0M−$184.0M−$91.0M−$127.0M
Tax rate (%)2.9%-0.3%-0.7%-0.2%0.0%-0.9%-0.8%-0.5%-0.8%-0.5%-1.1%7.1%
Net Profit−$123.0M−$171.0M−$132.0M−$134.0M−$133.0M−$151.0M−$115.0M−$180.0M−$129.0M−$185.0M−$92.0M−$118.0M
EPS−$1.52−$2.03−$1.52−$1.40−$1.39−$1.57−$1.17−$1.81−$1.29−$1.84−$0.90−$1.16

Over the 10 years reported for Ultragenyx Pharmaceutical Inc., cash stood at $434.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.48 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$541.0M$491.0M$720.0M$1.1B$1.8B$1.5B$1.5B$1.5B$1.5B$1.5B
Current Assets$498.0M$244.0M$522.0M$851.0M$1.3B$857.0M$884.0M$732.0M$817.0M$951.0M
Cash$161.0M$100.0M$113.0M$434.0M$714.0M$308.0M$133.0M$214.0M$174.0M$434.0M
Inventory$0$1.0M$7.0M$12.0M$13.0M$16.0M$27.0M$34.0M$45.0M$52.0M
Receivables$0$5.0M$13.0M$33.0M$23.0M$44.0M$40.0M$73.0M$122.0M$159.0M
Fixed Assets$17.0M$22.0M$20.0M$75.0M$114.0M$176.0M$260.0M$291.0M$266.0M$267.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$337.0M$144.0M$348.0M$355.0M$654.0M$726.0M$764.0M$564.0M$571.0M$318.0M
Other Assets$0$44.0M$44.0M$44.0M$44.0M$44.0M$44.0M$44.0M$44.0M$44.0M
Total Liabilities$67.0M$107.0M$111.0M$482.0M$605.0M$600.0M$1.2B$1.2B$1.2B$1.6B
Current Liabilities$60.0M$71.0M$75.0M$103.0M$190.0M$181.0M$261.0M$280.0M$344.0M$384.0M
Borrowings$0$0$0$37.0M$48.0M$42.0M$32.0M$43.0M$40.0M$1.3B
Other Liabilities$67.0M$107.0M$111.0M$445.0M$557.0M$558.0M$1.2B$1.2B$1.2B$329.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$474.0M$383.0M$609.0M$654.0M$1.2B$923.0M$352.0M$275.0M$255.0M−$80.0M

For Ultragenyx Pharmaceutical Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $472.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$161.0M−$254.0M−$291.0M−$345.0M−$132.0M−$339.0M−$380.0M−$475.0M−$414.0M−$466.0M
Investing Cash Flow$80.0M$54.0M−$37.0M−$38.0M−$223.0M−$268.0M−$438.0M$121.0M−$25.0M$230.0M
Financing Cash Flow$59.0M$9.0M$28.0M$324.0M$89.0M$40.0M$501.0M$8.0M$18.0M$0
Net Cash Flow$68.0M−$61.0M$12.0M$321.0M$290.0M−$417.0M−$172.0M$82.0M−$35.0M$253.0M
Free Cash Flow−$171.0M−$257.0M−$295.0M−$370.0M−$176.0M−$412.0M−$527.0M−$522.0M−$422.0M−$472.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.26
EV / EBITDA-6.54
FCF Yield-29.17%
Quick Ratio2.34
Interest Coverage-8.63
Return 1Y-48.68%
Return 3Y-58.22%
Return 5Y-78.42%

Ultragenyx Pharmaceutical Inc. (RARE) financials — frequently asked questions

What is Ultragenyx Pharmaceutical Inc.'s annual revenue?

Ultragenyx Pharmaceutical Inc. (RARE) reported annual revenue of $673.0M in its most recent fiscal year.

What is Ultragenyx Pharmaceutical Inc.'s net profit?

Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $575.0M in its most recent fiscal year.

What is RARE EV/EBITDA?

Ultragenyx Pharmaceutical Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -6.54. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RARE Overview RARE Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.